LDS/Medical Tests/Oncomine™ Dx Express™ Test for Non–Small Cell Lung Cancer (NSCLC) Treatment Monitoring

Oncomine™ Dx Express™ Test for Non–Small Cell Lung Cancer (NSCLC) Treatment Monitoring

The Oncomine Dx Express Test is an FDA-approved, fully automated next-generation sequencing (NGS) assay performed on the Ion Torrent Genexus Dx Integrated Sequencer. It delivers both companion diagnostic (CDx) results for EGFR exon 20 insertion mutations in NSCLC (for treatment with ZEGFROVY® (sunvozertinib) and broader tumor profiling biomarkers recommended by professional guidelines for multiple solid tumors. This includes substitutions, insertions, and deletions in 42 genes, copy number variants in 10 genes, and fusion or splice variants in 18 genes relevant in NSCLC, colorectal cancer, cholangiocarcinoma, and melanoma, among others.

  • Companion diagnostic for NSCLC patients with EGFR exon 20 insertion mutations eligible for ZEGFROVY® (sunvozertinib)
  • Aid in therapy treatment and monitoring for NSCLC and other cancer such colorectal cancer, cholangiocarcinoma, and melanoma
Positive for EGFR exon 20 insertion: Indicates eligibility for ZEGFROVY® therapy. Positive for other variants: Depending on variant and gene, may guide targeted therapy based on approved indications or clinical trials. Negative/No variants detected: No actionable alterations found; consider additional testing or alternative diagnostic options.

No pathogenic variants (mutations) detected

Next generation sequencing (NGS).

Formalin fixed paraffin embedded (FFPE) tissue samples.

Stability

FFPE samples are stable at room temperature for longer. 

Lung biopsy/fine needle aspiration, liquid biopsy or ctDNA, fluorescent in situ hybridization, PD-L1 immunohistochemistry.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login